Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean
Status:
Completed
Trial end date:
2020-10-30
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled parallel group study to evaluate efficacy and
safety of lasmiditan tablet compared to Placebo in the acute treatment of Migraine